[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608123":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":24,"responsibleParty":38,"collaborators":24,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":24,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":24,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":24,"overallStatus":60,"whyStopped":24,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":24},{"fullName":5,"class":6},"Qilu Hospital of Shandong University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase I Cardiac Rehabilitation Experimental Group","EXPERIMENTAL","Phase I cardiac rehabilitation（ low-intensity resistance training, breathing exercises, and bedside cycling） + drug therapy （Aspirin, Atorvastatin, Nitroglycerin）+ general treatment（quit smoking）",[13],"Other: drug therapy （Aspirin, Atorvastatin, Nitroglycerin）+ general treatment（quit smoking）",{"label":15,"type":16,"description":17,"interventionNames":18},"General Treatment Group","ACTIVE_COMPARATOR","drug therapy（Aspirin, Atorvastatin, Nitroglycerin）+ general treatment（quit smoking）",[13],[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"drug therapy （Aspirin, Atorvastatin, Nitroglycerin）+ general treatment（quit smoking）","The experimental group received Phase I cardiac rehabilitation intervention + medication treatment + general treatment, while the control group only received medication treatment + general treatment.",[15,9],null,[26],{"name":27,"affiliation":5,"role":28},"Yanyan Hu, Doctor","STUDY_CHAIR",[30,34],{"name":27,"role":31,"phone":32,"phoneExt":24,"email":33},"CONTACT","18560082229","yyhu78@163.com",{"name":35,"role":31,"phone":36,"phoneExt":24,"email":37},"Yuanyuan Wang, Doctor","18560082265","wangyuanyuan1204@email.sdu.edu.cn",{"type":39,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100608123","the-therapeutic-effect-of-phase-i-cardiac-rehabilitation-on-elderly-patients-with-chd-complicated-by-sarcopenia-100608123",false,"NCT07197463","The Therapeutic Effect of Phase I Cardiac Rehabilitation on Elderly Patients With CHD Complicated by Sarcopenia","Study on the Therapeutic Effect of Phase I Cardiac Rehabilitation on Elderly Patients With Coronary Heart Disease Complicated by Sarcopenia:A Single Center, Randomized Control Study in China","Inclusion Criteria:\n\n* Age ≥ 60 years;\n* Coronary heart disease confirmed by coronary CTA or coronary angiography, with stable condition within the past 8 hours, including: ① no new or recurrent chest pain; ② no further elevation of troponin level; ③ no new signs of decompensated heart failure (dyspnea at rest accompanied by moist rales); ④ no new malignant arrhythmias or dynamic changes in electrocardiogram. Basic vital signs are normal, including: ① resting heart rate of 50-100 beats per minute; ② resting blood pressure of 90-150\u002F60-100 mmHg (1 mmHg = 0.133 kPa); ③ oxygen saturation \\> 95%.\n* Meeting the diagnostic criteria for sarcopenia (2024 Edition of Chinese Guidelines for the Diagnosis and Treatment of Sarcopenia);\n* Having good compliance to ensure the completion of this study;\n* Being able to understand the purpose of the trial, voluntarily participating in the study and signing the informed consent form.\n\nExclusion Criteria:\n\n* Severe arrhythmia, decompensated heart failure, severe respiratory failure, untreated severe aortic stenosis, acute aortic dissection, resting hypertension with systolic and\u002For diastolic blood pressure \\> 200\u002F110 mmHg;\n* Mental disorders with limited cooperation ability; severe cognitive or behavioral disorders; end-stage diseases; acute diseases (e.g., acute infections, injuries) that restrict physical activity;\n* Poor compliance and inability to cooperate with the completion of this study.","ALL","60 Years","90 Years",{"count":51,"type":52},100,"ESTIMATED","INTERVENTIONAL",[55],"NA","The purpose of this clinical trial is to explore whether Phase I cardiac rehabilitation can treat elderly patients with coronary heart disease complicated by sarcopenia. It will also investigate the mechanism of Phase I cardiac rehabilitation. The main questions it aims to answer are:\n\n* Can Phase I cardiac rehabilitation enhance muscle strength ?\n* Can Phase I cardiac rehabilitation reduce in vivo inflammatory indicators? Researchers will compare the experimental group (Phase I cardiac rehabilitation + drug therapy + general treatment) with the control group (drug therapy + general treatment) to see if Phase I cardiac rehabilitation can treat elderly patients with coronary heart disease complicated by sarcopenia and reduce inflammatory indicators.\n\nParticipants will:\n\n* Receive Phase I cardiac rehabilitation training（mainly includes low-intensity resistance training, breathing training and bedside cycling） or conventional drug therapy for 3 consecutive months.\n* Undergo examinations 10 days after training, 1 month after discharge, and 3 months after discharge respectively.\n* Record changes in their muscle strength and blood inflammatory indicators.",[58,59],"Coronary Disease","Sarcopenia","NOT_YET_RECRUITING","2025-09-22",{"date":63,"type":64},"2025-09-29","ACTUAL",{"date":66,"type":52},"2025-10-10",{"date":68,"type":52},"2026-11-10",{"name":5,"class":6}]